)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Astria Therapeutics (ATXS) investor relations material
Astria Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Entered into a license agreement with Kaken Pharmaceutical for navenibart in Japan, including $16M upfront, up to $16M in milestones, and tiered royalties up to 30%.
BioCryst to acquire Astria in Q1 2026 for $8.55/share in cash plus 0.59 BioCryst shares per Astria share; transaction unanimously approved by both boards.
Navenibart's Phase 3 ALPHA-ORBIT trial is progressing, with topline results expected in early 2027; first patient enrolled in the ORBIT-EXPANSE extension trial.
Final Phase 1b/2 ALPHA-STAR results in 29 HAE patients show robust attack prevention and favorable safety profile for navenibart.
STAR-0310, an OX40 antagonist, demonstrated best-in-class profile in initial Phase 1a data.
Financial highlights
Astria receives a $16M upfront payment from Kaken, with additional $16M in potential commercialization and sales milestones.
Tiered royalties on net sales in Japan range from mid-teens to 30%.
Cash, cash equivalents, and short-term investments totaled $227.7M as of September 30, 2025, down from $344.3M a year prior.
Net loss for Q3 2025 was $31.6M, compared to $24.5M in Q3 2024.
Collaboration revenue was $0.7M for Q3 and YTD 2025, from the Kaken license agreement.
Outlook and guidance
The agreement is expected to provide significant non-dilutive funding and extend cash runway into 2028.
Astria anticipates Kaken's support will accelerate navenibart's development and regulatory approval in Japan.
Topline results from the ALPHA-ORBIT Phase 3 trial anticipated in early 2027.
Strategic alternatives being explored for STAR-0310 following positive Phase 1a results.
STAR-0310 strategic opportunities details
Kaken deal's total value and acquisition impact
Navenibart Q3M/Q6M dosing market impact
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Astria Therapeutics earnings date
Q4 20256 Mar, 2026
Next Astria Therapeutics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Astria Therapeutics Inc., formerly known as Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases. The company's lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein. Astria Therapeutics is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage